Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.52 |
| ▸ | ITGAV | P06756 | 8/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 5/20 | 0.35 |
| ▸ | ESR1 | P03372 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419565 | 0.91 | ITGB3 (0.48) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2785184 | 0.85 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6418707 | 0.85 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2784510 | 0.85 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2043373 | 0.84 | ITGB3 (0.73) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6784359 | 0.82 | ITGB3 (0.47) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6423446 | 0.81 | ITGB3 (0.71) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6419388 | 0.81 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6788320 | 0.81 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2050050 | 0.79 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2329821-A1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GlaxoSmithKline LLC (US) | 2011-06-08 | — | — | EP | disclosed |